CommercialCoverageMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Medical Policy
Effective date
Aug 10, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross has implemented new coverage policies for three medications: Zopapogene imadenovec-drba (Papzimeos), Narsoplimab (Yartemlea), and Gemcitabine (Avyxa, Avgemsi). All three policies become effective August 10, 2026.
Action Required
By August 10, 2026: Review the three new Arkansas Blue Cross policies at the provided URLs (policy numbers 2026007, 2026008, 2026009) to understand coverage criteria for Zopapogene imadenovec-drba, Narsoplimab, and Gemcitabine. Update billing and prior authorization workflows based on specific requirements found in each full policy document.